Peginterferon Alfa-2a Injection Shortage
Last Updated: March 3, 2025
Status: Current
Products Affected - Description
-
- Pegasys subcutaneous solution for injection, Summit SD, 180 mcg/0.5 mL, 0.5 mL prefilled syringe, 4 syringes in a monthly convenience pack, NDC 82154-0451-04
- Pegasys subcutaneous solution for injection, Summit SD, 180 mcg/mL, 1 mL single dose vial, NDC 82154-0449-01
Reason for the Shortage
-
- Summit SD is the distributor of Pegasys in the US. Pharma& manufactures Pegasys and is working to expand bio-manufacturing capabilities at the manufacturing plant.
Available Products
-
- There is insufficient supply for usual ordering
Estimated Resupply Dates
-
- Summit SD has Pegasys 180 mcg/mL 1 mL vials and 180 mcg/0.5 mL prefilled syringes on allocation. The company estimates additional product will be available in the first half of 2026.
Alternative Agents & Management
-
- Ropeginterferon alfa-2b-njft (Besremi) is a preferred alternative in patients with both low-risk (symptomatic) and high-risk polycythemia vera (PV) in the NCCN Clinical Practice Guidelines in Oncology. This information can be found at https://www.besremihcp.com/.
Updated
Updated March 3, 2025 by Leslie Jensen, PharmD, Drug Information Specialist. Created January 10, 2025 by Leslie Jensen, PharmD, Drug Information Specialist. © 2025, Drug Information Service, University of Utah, Salt Lake City, UT.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.